Evidence map›Paper›PMID 36558090›Full record

ArticleMolecules (Basel, Switzerland)2022

In Vitro and In Silico Studies for the Identification of Potent Metabolites of Some High-Altitude Medicinal Plants from Nepal Inhibiting SARS-CoV-2 Spike Protein.

Saroj Basnet, Rishab Marahatha, Asmita Shrestha, Salyan Bhattarai, Saurav Katuwal, Khaga Raj Sharma, Bishnu P Marasini, Salik Ram Dahal, Ram Chandra Basnyat, Simon G Patching and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. The Effect of Broccoli Glucosinolates Hydrolysis Products onInternational journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 4 countries.

Saroj BasnetCenter for Drug Design and Molecular Simulation Division, Kathmandu 44600, Nepal.ORCID 0000-0002-7508-2472
Rishab MarahathaCentral Department of Chemistry, Tribhuvan University, Kathmandu 44618, Nepal.ORCID 0000-0002-9065-159X
Asmita ShresthaCentral Department of Chemistry, Tribhuvan University, Kathmandu 44618, Nepal.ORCID 0000-0001-6759-2088
Salyan BhattaraiParaza Pharma, Inc., 2525 Avenue Marie-Curie, Montreal, QC H4S 2E1, Canada.
Saurav KatuwalCentral Department of Chemistry, Tribhuvan University, Kathmandu 44618, Nepal.ORCID 0000-0003-0570-865X
Khaga Raj SharmaCentral Department of Chemistry, Tribhuvan University, Kathmandu 44618, Nepal.ORCID 0000-0002-1555-0887
Bishnu P MarasiniNepal Health Research Council, Ramshah Path, Kathmandu 44600, Nepal.ORCID 0000-0001-6153-5234
Salik Ram DahalDepartment of Chemistry, Oklahoma State University, Still Water, OK 74078, USA.
Ram Chandra BasnyatCentral Department of Chemistry, Tribhuvan University, Kathmandu 44618, Nepal.
Simon G PatchingIndependent Researcher, Leeds LS2 9JT, UK.ORCID 0000-0001-6132-5317
Niranjan ParajuliCentral Department of Chemistry, Tribhuvan University, Kathmandu 44618, Nepal.ORCID 0000-0002-9233-6489
Tribhuvan University · NPOklahoma State University · USCenter for Molecular Dynamics - Nepal · NPNepal Health Research Council · NPParaza Pharma (Canada) · CAUniversity of Leeds · GB

Funding

University Grants Commission (Nepal) CoV-76/77-02
6 · The paper itself

Abstract

Despite ongoing vaccination programs against COVID-19 around the world, cases of infection are still rising with new variants. This infers that an effective antiviral drug against COVID-19 is crucial along with vaccinations to decrease cases. A potential target of such antivirals could be the membrane components of the causative pathogen, SARS-CoV-2, for instance spike (S) protein. In our research, we have deployed in vitro screening of crude extracts of seven ethnomedicinal plants against the spike receptor-binding domain (S1-RBD) of SARS-CoV-2 using an enzyme-linked immunosorbent assay (ELISA). Following encouraging in vitro results for

Indexed as

COVID-19Plants, MedicinalAltitudeAntiviral AgentsHumansMolecular Docking SimulationMolecular Dynamics SimulationNepalProtein BindingSARS-CoV-2Spike Glycoprotein, CoronavirusAntiviral AgentsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2molecular dockingmolecular dynamics simulationspike proteinTinospora cordifolia

Identifiers

PMID36558090
PMCPMC9786757
OpenAlexW4312209995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.